Insider Selling: Amicus Therapeutics, Inc. (NASDAQ:FOLD) Director Sells 15,000 Shares of Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) Director Margaret G. Mcglynn sold 15,000 shares of the business’s stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $6.99, for a total transaction of $104,850.00. Following the completion of the sale, the director now directly owns 38,034 shares of the company’s stock, valued at $265,857.66. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

NASDAQ FOLD opened at $7.17 on Thursday. The company has a current ratio of 4.09, a quick ratio of 3.90 and a debt-to-equity ratio of 1.27. The company has a 50 day moving average price of $8.62 and a 200 day moving average price of $9.86. Amicus Therapeutics, Inc. has a 52 week low of $6.66 and a 52 week high of $12.63.

Amicus Therapeutics (NASDAQ:FOLD – Get Rating) last posted its quarterly earnings data on Thursday, February 24th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.15). The firm had revenue of $82.15 million for the quarter, compared to the consensus estimate of $82.57 million. Amicus Therapeutics had a negative return on equity of 87.21% and a negative net margin of 81.98%. During the same quarter last year, the firm earned ($0.27) EPS. As a group, equities analysts forecast that Amicus Therapeutics, Inc. will post -0.83 EPS for the current year.

A number of institutional investors have recently modified their holdings of the business. Perceptive Advisors LLC increased its stake in Amicus Therapeutics by 14.9% during the 3rd quarter. Perceptive Advisors LLC now owns 26,559,443 shares of the biopharmaceutical company’s stock valued at $253,643,000 after purchasing an additional 3,438,114 shares in the last quarter. Wellington Management Group LLP increased its stake in Amicus Therapeutics by 55.0% during the 3rd quarter. Wellington Management Group LLP now owns 24,295,698 shares of the biopharmaceutical company’s stock valued at $232,024,000 after purchasing an additional 8,624,249 shares in the last quarter. Redmile Group LLC increased its stake in Amicus Therapeutics by 9.2% during the 4th quarter. Redmile Group LLC now owns 22,716,086 shares of the biopharmaceutical company’s stock valued at $262,371,000 after purchasing an additional 1,916,783 shares in the last quarter. BlackRock Inc. increased its stake in Amicus Therapeutics by 1.1% during the 4th quarter. BlackRock Inc. now owns 19,810,348 shares of the biopharmaceutical company’s stock valued at $228,810,000 after purchasing an additional 224,150 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Amicus Therapeutics by 0.4% during the 4th quarter. JPMorgan Chase & Co. now owns 15,343,828 shares of the biopharmaceutical company’s stock valued at $177,222,000 after purchasing an additional 60,770 shares in the last quarter.

Several equities research analysts have issued reports on FOLD shares. The Goldman Sachs Group initiated coverage on shares of Amicus Therapeutics in a research report on Wednesday, April 13th. They issued a “neutral” rating for the company. Cantor Fitzgerald reduced their price target on shares of Amicus Therapeutics from $16.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, January 13th. StockNews.com initiated coverage on shares of Amicus Therapeutics in a report on Thursday, March 31st. They issued a “hold” rating for the company. Finally, SVB Leerink reduced their price target on shares of Amicus Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Thursday, February 24th. Five investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Amicus Therapeutics has an average rating of “Buy” and an average target price of $15.14.

Amicus Therapeutics Company Profile (Get Rating)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.

Featured Stories